Boston Scientific Stock News

Related Stocks: PHVS , FOLD , KNTE , IOVA , AKUS , LUNG , BSX , VECT , RCKT , ANNX , INZY , PTGX , LEGN , EAR , ABCL , XENT ,

Overview of Global Metal Stents Market: DBMR team offers customization of Metal Stents Market report according to the business needs. Contact sales team, who will guarantee to get a report that suits the necessities. The Market analysis and competitor analysis helps

Market Players for Global Laparoscopy Devices Market Stryker Corporation, Karl Storz GmbH & Co KG, Boston Scientific Corporation, Medtronic PLC, Intuitive Surgical, (Japan), Karl Storz GmbH, Olympus Corporation, Microline Surgical, Medtronic PLC. Johnson & Johnson, Olympus Corporation, Conmed Corporation Market Players for Global Laparoscopy Devices Market Stryker Corporation, Karl Storz GmbH & Co KG, Boston Scientific Corporation, Medtronic PLC, Intuitive Surgical, (Japan), Karl Storz GmbH, Olympus Corporation, Microline Surgical, Medtronic PLC. Johnson & Johnson, Olympus Corporation, Conmed Corporation

Pain Management and Surgical Devices market is expected to witness market growth at a rate of 6.51% in the forecast period of 2021 to 2028 and is expected to reach USD 8584.89 million by 2028. For a constantly increasing business growth

Ambulatory Cardiac Monitoring Devices Market: Introduction According to the report, the global ambulatory cardiac monitoring devices market was valued at US$ 13.5 Bn in 2020 and is projected to expand at a moderate CAGR from 2021 to 2031. Ambulatory cardiac monitor

Urology Disorders are on a rise and that is leading the global urology devices market on an upward growth curve. It is set to chart a healthy CAGR (Compound Annual Growth Rate) of 7.1% between 2018 and 2026, as per

MARLBOROUGH, Mass., Nov. 8, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.

Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.

Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q3 2021 Results - Earnings Call Transcript

Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.

Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.93 billion in Q3 of 2021, almost in line with the Wall Street estimate of $2.97 billion. Sales increased 10.3% Y/Y on a reported b

Boston Scientific (BSX) delivered earnings and revenue surprises of 2.50% and -1.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Boston Scientific Corp. BSX, -0.38% rose 0.4% in premarket trading Wednesday, after the medical device company reported third-quarter profit that topped expectations, but sales that came up

Boston Scientific is scheduled to report its Q3 2021 results on Wednesday, Oct 27. We expect the company to report revenues and earnings in-line with the consensus estimates, driven by a rebound in vo

Within Urology/ Pelvic Health, Boston Scientific (BSX) is expected to have registered strong sales growth in Stone, Prostate Health and Pelvic Health franchises.